IDEAYA Biosciences Inc
NASDAQ:IDYA

Watchlist Manager
IDEAYA Biosciences Inc Logo
IDEAYA Biosciences Inc
NASDAQ:IDYA
Watchlist
Price: 29.47 USD -3.35% Market Closed
Market Cap: 2.5B USD
Have any thoughts about
IDEAYA Biosciences Inc?
Write Note

IDEAYA Biosciences Inc
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

IDEAYA Biosciences Inc
Income from Continuing Operations Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
IDEAYA Biosciences Inc
NASDAQ:IDYA
Income from Continuing Operations
-$178.1m
CAGR 3-Years
-69%
CAGR 5-Years
-35%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Income from Continuing Operations
$5.1B
CAGR 3-Years
-12%
CAGR 5-Years
9%
CAGR 10-Years
3%
Gilead Sciences Inc
NASDAQ:GILD
Income from Continuing Operations
$113m
CAGR 3-Years
-75%
CAGR 5-Years
-47%
CAGR 10-Years
-36%
Amgen Inc
NASDAQ:AMGN
Income from Continuing Operations
$4.2B
CAGR 3-Years
-9%
CAGR 5-Years
-12%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Income from Continuing Operations
-$479.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
2%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Income from Continuing Operations
$4.7B
CAGR 3-Years
-13%
CAGR 5-Years
17%
CAGR 10-Years
30%

See Also

What is IDEAYA Biosciences Inc's Income from Continuing Operations?
Income from Continuing Operations
-178.1m USD

Based on the financial report for Sep 30, 2024, IDEAYA Biosciences Inc's Income from Continuing Operations amounts to -178.1m USD.

What is IDEAYA Biosciences Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-35%

Over the last year, the Income from Continuing Operations growth was -73%. The average annual Income from Continuing Operations growth rates for IDEAYA Biosciences Inc have been -69% over the past three years , -35% over the past five years .

Back to Top